Medclair (MCLR) Q3 2026 earnings summary

Executive summary

• Q3 order intake rose 40% YoY to SEK 20.9m and net sales rose 28% to SEK 13.5m; EBITDA was SEK 0.7m amid expansion investments.

• Installed base reached ~700 installations across 250 customers in 20 countries, supporting service, consumables, repairs and cross-selling opportunities.

• Recurring revenue reached ~SEK 3.6m annualized; new agreements signed in Q3 add ~SEK 0.9m annual recurring revenue, with ~SEK 1m more estimated from installed equipment.

Financial highlights

• Q3 net sales SEK 13.5m vs SEK 10.5m; EBITDA SEK 0.7m vs SEK 1.8m; operating profit SEK -0.7m vs SEK 0.3m; net profit SEK -0.8m vs SEK 0.3m.

• 9M net sales rose 10% YoY to SEK 46.0m; EBITDA was SEK 7.0m vs SEK 11.8m; operating profit SEK 2.6m vs SEK 7.3m; net profit SEK 2.6m vs SEK 6.8m.

• Q3 EPS was SEK -0.008 vs SEK 0.004; 9M EPS was SEK 0.03 vs SEK 0.08.

• Q3 order intake was SEK 20.9m vs SEK 14.9m; 9M order intake was SEK 62.1m vs SEK 49.6m; quarter-end backlog SEK 26.4m.

Outlook and guidance

• FY 2026 net sales are expected to exceed FY 2025's SEK 52.1m by a good margin; strong order intake continued into early Q4.

• Most of the SEK 26.4m backlog is expected to be delivered in Q4 2026 and Q1 2027.

• First commercial photocatalytic products are planned for 2H 2027, starting in Dental; additional products are planned during 2027.

• Growth outlook rests on international expansion, a broader offering and higher recurring revenue and revenue per installation.